Elevating Healthcare

We help healthcare players navigate transactions and unlock growth opportunities through market intelligence and strategic diligence

How We Work

About us

Atain & Company is an independent advisory firm specializing in investment due diligence and value creation for innovative and growth-oriented companies.

We work with a variety of clients, from financial and strategic buyers looking to acquire and grow businesses, to entrepreneurs and corporates addressing strategic challenges. We help source deals and conduct due diligence to support investment decisions. Post-deal, we build strategies that drive growth, efficiency, and competitiveness.

As investors ourselves, we are committed to having a sustainable impact and helping clients embed ESG in value creation to achieve lasting profitability and tangible social benefits.

Our Services

  • We help investors find, qualify, and engage healthcare and life sciences investment opportunities in the DACH and Benelux markets, leveraging a data-driven approach and cutting-edge AI solutions

    • Market assessment

    • Off-market opportunity search

    • Pipeline tracking

    • Investment case development

    • Management access

  • We guide investors and industry players with tailored commercial due diligence to evaluate value, risks, and ensure strategic growth potential

    • Market & competitive analysis

    • Customer & KOL interviews

    • Pre- / feasibility studies

    • CDD: Red-flag / Full / Vendor

  • We equip companies with strategies and value-creation plans to grow the core business and determine an approach for unlocking new strategic and operational potential

    • Revenue growth strategy

    • Business development acceleration

    • Strategic planning

    • PMO setup & running

    • M&A clean team services

Work With Us

HEALTHCARE SUBSECTORS COVERED

Biopharma &
Life Science
Services

  • Contract development

  • Contract manufacturing

  • Contract research

  • Pharma services

  • Diagnostic products

  • Specialty pharma

  • Biotechnology

  • Generics

Broader
Health Care Ecosystem

  • Medical product & equipment

  • Physicians solutions

  • Patient engagement

  • Animal health

  • Distribution

  • Health education

  • Adjacent industries

Our clients

“We support clients in acquiring healthcare companies and unlocking their full commercial potential.”

— Dr. Tetiana Kosten

Tetiana Kosten is the founder and director of Atain. She established the consultancy in 2020, supporting investors through the fast-paced post-pandemic investment surge.

Tetiana has 10 years of professional consulting experience, specialising in commercial due diligence and strategy. She developed a strong interest in healthcare investments while working at Roland Berger in Munich. Her track record is built on a foundation rigorously refined through over 50 due diligence projects, addressing investors’ requirements for both mature and early-stage companies.

Tetiana holds an MSc in Biotechnology from Shevchenko University in Kyiv and a PhD from the Max Delbrück Center and Free University in Berlin. She speaks English and German and is committed to promoting women’s entrepreneurship

Latest news

We're proud to support our clients journey in building capabilities across their organizations, creating impact that extends beyond financial and operational success. Here’s a glimpse into that journey. 

Private Equity

Private markets health check: rebounding with strength in 2025

What headwinds and tailwinds are impacting fundraising, deal activity, value creation, and investment performance in private markets in 2024 and the year ahead

Insights • January 2025
Explore
 
Medical devices

Operational and legal due diligence on manufacturers of medical products

Learn how our due diligence services have helped clients across a wide range of products and geographies find quality, reliable, and financially viable manufacturers

Case study • August 2024
Explore
 
Biopharmaceuticals

Engaging payers in rare disease to prepare the market for gene therapy

The global pharma engaged us to assess how the company could interact with payers and payer advisory stakeholders to advance the field prior to launch

Case study • March, 2024
Explore
Seed Investments

Tracing the origins of new ventures in intellectual property landscape

What challenges and opportunities are shaping Ukraine’s innovation landscape, and how can EU accession drive deeper technological advancements?

Report • August 2024
Explore
Explore

Collaborate. Innovate. Grow.

Join our network

We are proud to have built a network of thousands of industry experts who have held senior roles in private equity, venture capital, management, or the industry, and we are excited to bring their valuable expertise to our deals and projects. Are you interested in joining our team? Contact us!

Meet us